Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric subcutaneous golimumab study in moderately to severely active ulcerative colitis
NL-OMON40329Phase 1Active, not recruiting
- Sponsor
- Janssen Biologics B.V.
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of golimumab in autoimmune colitis, sponsored by Janssen Biologics B.V. Primary endpoints: Serum golimumab concentration at Week 6 and AUC from 0 to 6 weeks. Started Nov 2013; status: active, not recruiting.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON40329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40329.